Loan Agreement between Feedback AG Neuer Wall 54 20354 Hamburg Represented by Dr. Christoph Ludz and Thomas Striepe, Members of the Board (subsequently „FeedBack”) and Sangui BioTech International, Inc. Alfred-Herrhausen-Str.44 58455 Witten...Loan Agreement • June 14th, 2007 • Sangui Biotech International Inc • Pharmaceutical preparations
Arabian companies will start selling Sangui products in the course of next few monthsMarketing and Distribution Agreement • June 14th, 2007 • Sangui Biotech International Inc • Pharmaceutical preparations
Witten, Dubai, May 23, 2007 – Comprehensive marketing and distribution agreements to this effect have been signed between Sheikh Al Mudhareb, TYCOON Consulting (UK) Ltd. and SanguiBioTech GmbH after a series of presentations and in depth negotiations in Sharjah and Dubai. Products covered by the terms of the contracts include the whole range of Sangui’s present and future cosmetics products as well as the range of medical products if and when certified for distribution in these markets. This refers in particular to Sangui’s ChitoSkin wound pads based on bovine gelatine and the HemoSpray based on camel blood.
Loan Agreement Between Feedback AG Hamburg Represented by Dr. Christoph Ludz and Thomas Striepe, Members of the Board (subsequently „FeedBack”) And Sangui BioTech International, Inc. Alfred-Herrhausen-Str.44 58455 Witten Represented by Prof. Wolfgang...Loan Agreement • June 14th, 2007 • Sangui Biotech International Inc • Pharmaceutical preparations
COOPERATION AND MARKETING AGREEMENT between Karl Beese (GmbH & Co.), Barsbüttel (henceforth “Beese”) and Sangui GmbH, Witten (henceforth “Sangui”) PreambleCooperation and Marketing Agreement • June 14th, 2007 • Sangui Biotech International Inc • Pharmaceutical preparations
Sangui has developed a chitosan based wound pad (Chitoskin). Beese has already established processes to sterilize and package such wound pads on behalf of Sangui. Beese is interested in marketing the Chitoskin product. The parties agree that these wound pads have unique properties which significantly differentiate them from other existing wound pads. Related patents have been applied for on an international level.
Loan Agreement between FID Esprit AG Rosengartenstrasse 4 CH-8608 Bubikon Represented by Axel Kutscher (subsequently „FID Esprit”) and Sangui BioTech International, Inc. Alfred-Herrhausen-Str.44 58455 Witten Represented by Prof. Wolfgang Barnikol...Loan Agreement • June 14th, 2007 • Sangui Biotech International Inc • Pharmaceutical preparations
HEADS OF AGREEMENTHeads of Agreement • June 14th, 2007 • Sangui Biotech International Inc • Pharmaceutical preparations • Hamburg
Sangui has invented and developed certain haemoglobin based products and know-how for blood related pharmaceuticals/drug products and medical products such as an artificial oxygen carrier (Artificial Blood Additive), in the following “Additive” and wound protection devices such as Hemo-Spray, wound cleaner liquid/gel and Chitoskin wound pads, in the following “Hemo, WCL/G and Chito”. Sangui holds all related intellectual property rights including – but not limited to – various patents and patents rights pending for registration as well as the production know-how. The Additive as well as the Hemo, WCL/G and Chito shall obtain proper registration either as pharmaceuticals/drug products or medical products in order to be marketed and applied to patients in the whole world.
